---
title: The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine
nct_id: NCT02115958
overall_status: COMPLETED
phase: PHASE1, PHASE2
sponsor: Fuda Cancer Hospital, Guangzhou
study_type: INTERVENTIONAL
primary_condition: Neoplasms, Lung
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02115958.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02115958"
ct_last_update_post_date: 2019-09-12
last_seen_at: "2026-05-12T07:31:53.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine

**Official Title:** Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic of the Nasopharynx

**NCT ID:** [NCT02115958](https://clinicaltrials.gov/study/NCT02115958)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1, PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 40
- **Lead Sponsor:** Fuda Cancer Hospital, Guangzhou
- **Collaborators:** University of Michigan
- **Conditions:** Neoplasms, Lung
- **Start Date:** 2014-03
- **Completion Date:** 2015-05
- **CT.gov Last Update:** 2019-09-12

## Brief Summary

Most studies of cancer stem cells (CSC) involve the inoculation of cells from human tumors into immunosuppressed mice, preventing an assessment on the immunologic interactions and effects of CSCs. In this study, the investigators examined the vaccination effects produced by CSC-enriched populations from histologically distinct murine tumors after their inoculation into different syngeneic immunocompetent hosts. Enriched CSCs were immunogenic and more effective as an antigen source than unselected tumor cells in inducing protective antitumor immunity.Immune sera from CSC-vaccinated hosts contained high levels of IgG which bound to CSCs, resulting in CSC lysis in the presence of complement.CTLs generated from peripheral blood mononuclear cells or splenocytes harvested from CSC-vaccinated hosts were capable of killing CSCs in vitro. Mechanistic investigations established that CSC-primed antibodies and T cells were capable of selective targeting CSCs and conferring antitumor immunity.

## Detailed Description

To assess the feasibility of generating CSC-loaded DC vaccines for clinical use, the investigators will harvest peripheral blood and tumor specimen from patients with Nasopharyngeal Cancer. The investigators will purify T, B cells and generate DCs from the PBMCs of the nasopharyngeal cancer patient.On the other hand, investigators will isolate ALDHhigh and ALDHlow tumor cells from the tumor specimen of the nasopharyngeal cancer patient using a similar protocol as investigators reported .

Aim 1: To demonstrate, in vitro, the relative cellular anti-nasopharyngeal cancer CSC immunity induced by nasopharyngeal cancer CSC-DC primed cytotoxic T cells.

Aim 2: To determine, in vitro, specific binding and lysis of nasopharyngeal cancer CSCs by antibodies produced by purified B cells from PBMCs stimulated with nasopharyngeal cancer CSC-DC.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* 1.patients are greater than 18 years of age, with advanced local disease (T3-T4N0-1M0), nodal disease (T1-T2N2-3M0) and loco-regional disease (T3-T4N2-3M0) at onset but presently controlled by standard therapy (combination of chemotherapy and radiotherapy) or with completely resected metastatic disease.

  2.Pathologic confirmation of nasopharyngeal carcinoma by the NCI Laboratory of Pathology (NPC).

  3.serum creatinine of 2.0 mg/dl or less. 4.Total bilirubin 1.6 mg/dl or less, except for patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.

  5.WBC 3000/mm(3) or greater. 6.platelet count 90,000 mm(3) or greater. 7.serum AST/ALT less than three times normal. 8.ECOG performance status of 0 or 1. 9.Patients of both genders must be willing to practice effective birth control during this trial because the potential for teratogenic effects are unknown.

  10.Patients may have had prior adjuvant treatment or may have had treatment for metastatic disease and are now with no evidence of disease, including chemotherapy or biotherapy, as long as 1 month has elapsed since prior systemic therapy.

Exclusion Criteria:

1\. Patients who test positive for Hepatitis B virus, Hepatitis C virus or HIV. 2. level 3 hypertension; 3. severe coronary disease; 4. myelosuppression; 5. respiratory disease; 6. brain metastasis; 7. chronic infections
```

## Arms

- **non-cancer stem cell vaccine** (PLACEBO_COMPARATOR) — The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
- **giving low dose vaccine** (EXPERIMENTAL) — The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
- **giving middle dose vaccine** (EXPERIMENTAL) — The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
- **giving high dose vaccine** (EXPERIMENTAL) — The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.

## Interventions

- **cancer stem cell vaccine** (BIOLOGICAL)

## Primary Outcomes

- **The primary study purpose to determine the safety of immunization with cancer stem cells vaccine by the number of participants with adverse events** _(time frame: up to 3 months)_

## Secondary Outcomes

- **The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements** _(time frame: 1 month)_

## Locations (1)

- Biological treatment center in Fuda cancer hospital, Guangzhou, Guangdong, China

## Recent Field Changes (last 30 days)

- `status.completionDate` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.biological treatment center in fuda cancer hospital|guangzhou|guangdong|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02115958.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02115958*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*